Opioids and Other Central Nervous System-Active Polypharmacy in Older Adults in the United States.

Lauren B Gerlach, Mark Olfson, Helen C Kales, Donovan T Maust
Author Information
  1. Lauren B Gerlach: Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.
  2. Mark Olfson: Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York.
  3. Helen C Kales: Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.
  4. Donovan T Maust: Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.

Abstract

OBJECTIVES: To determine patterns of and trends in contributions to central nervous system (CNS) polypharmacy, defined by the Beers Criteria as three or more CNS-active medications of each medication class, of adults aged 65 and older seen in U.S. outpatient medical practices.
DESIGN: National Ambulatory Medical Care Survey (2004-2013).
SETTING: U.S. outpatient medical care.
PARTICIPANTS: Visits by older adults to outpatient physicians (N = 97,910).
MEASUREMENTS: Visits including three or more CNS medications including antipsychotics, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonist hypnotics (NBRAs), tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and opioids. The proportion of CNS polypharmacy that each medication class contributed during 2011 to 2013 was determined, and then logistic regression was used to determine trends from 2004 to 2013 in the contribution of individual medication classes to such polypharmacy.
RESULTS: Of recent CNS polypharmacy visits, 76.2% included an opioid, and 61.8% included a benzodiazepine; 66.0% of the polypharmacy visits with benzodiazepines included opioids, and 53.3% of the polypharmacy visits with opioids included benzodiazepines. Between 2011 and 2013, opioid and benzodiazepine co-prescribing occurred at approximately 1.50 million visits (95% confidence interval (CI) = 1.23-1.78 million) annually. From 2004 (reference) to 2013, the proportion of polypharmacy visits with opioids rose from 69.6% to 76.2% (adjusted odds ratio = 2.15, 95% CI = 1.19-3.91, P = .01), and the corresponding proportion that included benzodiazepines fell. Of the polypharmacy visits, the odds of SSRI, NBRA, and antipsychotic use were unchanged, and that of TCAs decreased.
CONCLUSION: In older adults, opioid use appears to be largely driving the recent national increase in CNS polypharmacy. Although concomitant use of opioids and benzodiazepines is associated with greater mortality, they are the most common contributors to CNS polypharmacy in older adults.

Keywords

References

  1. J Am Geriatr Soc. 2015 Nov;63(11):2227-46 [PMID: 26446832]
  2. Arch Intern Med. 2009 Nov 23;169(21):1952-60 [PMID: 19933955]
  3. J Clin Psychiatry. 2013 Sep;74(9):932-9 [PMID: 24107767]
  4. Pharmacotherapy. 2016 Nov;36(11):1123-1131 [PMID: 27711982]
  5. Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):637-45 [PMID: 26711081]
  6. BMJ. 2015 Jun 10;350:h2698 [PMID: 26063215]
  7. Arch Intern Med. 2010 Oct 11;170(18):1648-54 [PMID: 20937924]
  8. J Gerontol A Biol Sci Med Sci. 2009 Apr;64(4):492-8 [PMID: 19196642]
  9. NCHS Data Brief. 2014 Sep;(166):1-8 [PMID: 25228059]
  10. Health Aff (Millwood). 2011 Aug;30(8):1434-42 [PMID: 21821561]
  11. JAMA Intern Med. 2014 Jun;174(6):890-8 [PMID: 24733354]
  12. Arch Gen Psychiatry. 2012 Dec;69(12):1247-56 [PMID: 22868273]
  13. Am J Geriatr Psychiatry. 2011 Oct;19(10):851-8 [PMID: 21946801]
  14. Arch Intern Med. 1997 Jul 28;157(14):1531-6 [PMID: 9236554]
  15. J Clin Psychiatry. 2017 Apr;78(4):e363-e371 [PMID: 28448697]
  16. Am J Psychiatry. 2001 Jun;158(6):892-8 [PMID: 11384896]
  17. Psychiatr Serv. 2009 Aug;60(8):1015-23 [PMID: 19648187]
  18. BMJ. 2005 Nov 19;331(7526):1169 [PMID: 16284208]
  19. JAMA Intern Med. 2017 Apr 1;177(4):583-585 [PMID: 28192559]
  20. Am J Public Health. 2016 Nov;106(11):2019-2025 [PMID: 27631754]
  21. Am J Geriatr Psychiatry. 2014 Jun;22(6):531-9 [PMID: 24211029]
  22. J Am Geriatr Soc. 2009 Feb;57(2):243-50 [PMID: 19207141]

Grants

  1. K08 AG048321/NIA NIH HHS

MeSH Term

Aged
Aged, 80 and over
Analgesics, Opioid
Benzodiazepines
Central Nervous System Agents
Drug Interactions
Female
Humans
Male
Polypharmacy
Potentially Inappropriate Medication List
Practice Patterns, Physicians'
Surveys and Questionnaires
United States

Chemicals

Analgesics, Opioid
Central Nervous System Agents
Benzodiazepines

Word Cloud

Created with Highcharts 10.0.0polypharmacyCNSbenzodiazepinesopioidsvisits=includedadultsolder2013medicationoutpatientbenzodiazepineproportionopioid1usedeterminetrendsthreemedicationsclassUSmedicalVisitsincludingTCAs20112004recent762%million95%CIoddsOBJECTIVES:patternscontributionscentralnervoussystemdefinedBeersCriteriaCNS-activeaged65seenpracticesDESIGN:NationalAmbulatoryMedicalCareSurvey2004-2013SETTING:carePARTICIPANTS:physiciansN97910MEASUREMENTS:antipsychoticsnonbenzodiazepinereceptoragonisthypnoticsNBRAstricyclicantidepressantsselectiveserotoninreuptakeinhibitorsSSRIscontributeddeterminedlogisticregressionusedcontributionindividualclassesRESULTS:618%660%533%co-prescribingoccurredapproximately50confidenceinterval23-178annuallyreferencerose696%adjustedratio21519-391P01correspondingfellSSRINBRAantipsychoticunchangeddecreasedCONCLUSION:appearslargelydrivingnationalincreaseAlthoughconcomitantassociatedgreatermortalitycommoncontributorsOpioidsCentralNervousSystem-ActivePolypharmacyOlderAdultsUnitedStates

Similar Articles

Cited By